Not Yet Recruiting
Primary Outcome Measures Primary endpoint – To evaluate the activity of neo-adjuvant treatment by the determination of pathological complete response rate (pCR) Secondary Outcome Measures Secondary endpoint – To further evaluate the activity of neo-adjuvant treatment in terms of major pathological response. Secondary endpoint – To further evaluate the activity of neo-adjuvant treatment in terms…
Primary Outcome Measures To determine stabilization or disease improvement rates in participants with early-stage mesotheliomas arising in the context of BAP1 CPDS following decitabine/cedazuridine treatment Secondary Outcome Measures To evaluate the safety of decitabine/cedazuridine To determine PFS in participants receiving decitabine/cedazuridine Inclusion Criteria Participants with history of germline BRCA1-Associated Protein-1 (BAP1) mutations. Histologically confirmed by…
Primary Outcome Measures Objective Response Rate (ORR) defined as the percentage of participants who achieve a best overall response of complete response or partial response assessed according to mRECIST v1.1 for assessment of response in malignant pleural mesothelioma. Up to 36 months Secondary Outcome Measures Progression Free Survival (PFS) defined as the time between the…
Primary Objective The primary objective is to test whether the combination of platinum-based chemotherapy and pemetrexed with durvalumab / tremelimumab or durvalumab / tremelimumab alone improves recurrence-free survival for patients with resectable MPM compared to historical, published data for surgery with chemotherapy. Secondary Objective The secondary objectives are to determine the safety of and whether…
Primary Outcome Measures Rate of patients who decide to enroll in a mesothelioma medical study. [ Time Frame: 3 months ] Number of mesothelioma patients who remain in clinical trial until completion. [ Time Frame: 12 months ] Inclusion Criteria Must have a medical diagnosis of mesothelioma that has been confirmed by a physician. Aged ≥ 18 years old and ability to provide…
Primary Outcome Measures Proportion of patients that experienced (S)AEs possibly, probably or definitely related to pemetrexed and/or cisplatin/carboplatin and/or atezolizumab and/or WT1/DC vaccination [ Time Frame: through study completion, an average of 2 years ] The relationship of an AE to the investigational agents will be determined by the Investigator as either related or non-related, based on their clinical…
Primary Outcome Measures Phase 1 Maximum Tolerated Dose [ Time Frame: 28 days ] To determine the maximum tolerated dose (MTD) of TNG462 Phase 1 Dosing Schedule [ Time Frame: 28 days ] To determine the dosing schedule of TNG462 Phase 2 Anti-neoplastic Activity [ Time Frame: 16 weeks ] To assess anti-neoplastic activity of TNG462 in patients with MTAP-deleted advanced solid tumors by RECIST v1.1 Secondary…
Primary Outcome Measures Number of patients tolerating dose levels (maximum tolerated dose; MTD) in each of the combinations [ Time Frame: Assessed from baseline to 30 days after last dose of study drug ] MTD of NUC-3373 in each of the combinations in each patient Number of patients reporting treatment-emergent adverse events (TEAEs) in each of the combinations [ Time Frame: Assessed…
Primary Outcome Measures Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0 [ Time Frame: through study completion; an average of 1 year. ] Inclusion Criteria Signed consent to long-term follow-up on protocol PA17-0483 Patients with advanced clear cell renal cell carcinoma, osteosarcoma or mesothelioma, with an…
There might be more options for treating mesothelioma. A study looked at the combination of Opdivo and Yervoy after surgery. The study was performed at the Hyogo College of Medicine in Japan. Opdivo and Yervoy, which were recently approved for the treatment of mesothelioma, improved survival when administered after surgery. The six-month survival was 87…
- « Previous
- 1
- 2
- 3
- Next »
